APA (7th ed.) Citation

AS, G., A, I., M, B., M, S., S, P., HR, S., . . . E, R. (2026). Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: A phase I clinical trial. Cancer immunology, immunotherapy : CII, 75(4), . https://doi.org/10.1007/s00262-025-04285-9

Chicago Style (17th ed.) Citation

AS, Ghasabeh, et al. "Allogeneic CD56 + cell Infusion as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed/refractory Acute Myeloid Leukemia: A Phase I Clinical Trial." Cancer Immunology, Immunotherapy : CII 75, no. 4 (2026). https://doi.org/10.1007/s00262-025-04285-9.

MLA (9th ed.) Citation

AS, Ghasabeh, et al. "Allogeneic CD56 + cell Infusion as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed/refractory Acute Myeloid Leukemia: A Phase I Clinical Trial." Cancer Immunology, Immunotherapy : CII, vol. 75, no. 4, 2026, https://doi.org/10.1007/s00262-025-04285-9.